14.17  0.02 (0.14%)		12-01 16:00
Open: 14.04 High: 14.17 Volume: 830,716		Pre. Close: 14.15 Low: 14.03 Market Cap: 44,462(M)

Short term
Mid term
Targets	6-month :	16.55	1-year :	19.33
Resists	First :	14.17	Second :	16.55
Pivot price	13.93
Supports	First :	13.65	Second :	13.32
MAs	MA(5) :	14.1	MA(20) :	13.89
	MA(100) :	14.94	MA(250) :	15.57
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	95.1	D(3) :	94.1
RSI	RSI(14): 53.1
52-week	High :	17.14	Low :	13.18

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TAK ] has closed below upper band by 16.5%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.19 - 14.24	14.24 - 14.28
Low:	13.89 - 13.95	13.95 - 14.01
Close:	14.07 - 14.17	14.17 - 14.26

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Sat, 02 Dec 2023
Renaissance Technologies LLC Grows Stock Position in Takeda ... - MarketBeat

Wed, 29 Nov 2023
Validea's Top Health Care Stocks Based On Peter Lynch - 11/29/2023 - Nasdaq

Mon, 27 Nov 2023
Takeda to Present Data at 65th American Society of Hematology ... - Business Wire

Fri, 17 Nov 2023
The European Commission Approves Label Update for TAKHZYRO ... - PR Newswire

Tue, 14 Nov 2023
Takeda wins second FDA approval in two days with Adzynma for ... - BioWorld Online

Fri, 10 Nov 2023
Neurocrine Biosciences shares drop as trial failures may 'stunt ... - Morningstar

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Shares Out	0 (M)
Shares Float	3,140 (M)
Held by Insiders	1.55e+009 (%)
Held by Institutions	0 (%)
Shares Short	8,370 (K)
Shares Short P.Month	0 (K)

EPS	0.4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4
Profit Margin	4.6 %
Operating Margin	-4.8 %
Return on Assets (ttm)	2.4 %
Return on Equity (ttm)	2.7 %
Qtrly Rev. Growth	4 %
Gross Profit (p.s.)	0
Sales Per Share	6.19
EBITDA (p.s.)	1.79
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	963,230 (M)

PE Ratio	34.56
PEG Ratio	0
Price to Book value	3.54
Price to Sales	2.28
Price to Cash Flow	0.01

Dividend	0
Forward Dividend	9.46e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.